1-4 of 4
Purva Bali
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

Free
Warren Fiskus, Yuan Ren, Alex Mohapatra, Purva Bali, Aditya Mandawat, Rekha Rao, Bryan Herger, Yonghua Yang, Peter Atadja, Jie Wu, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4882–4890.
https://doi.org/10.1158/1078-0432.CCR-06-3093
Published: 15 August 2007
View articletitled, Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90
Open the PDF for Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90 in another window
Journal Articles

Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

Free
Warren Fiskus, Michael Pranpat, Maria Balasis, Purva Bali, Veronica Estrella, Sandhya Kumaraswamy, Rekha Rao, Kathy Rocha, Bryan Herger, Francis Lee, Victoria Richon, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5869–5878.
https://doi.org/10.1158/1078-0432.CCR-06-0980
Published: 04 October 2006
View articletitled, Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells
Open the PDF for Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells in another window
Journal Articles

Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

Free
Purva Bali, Michael Pranpat, Ramona Swaby, Warren Fiskus, Hirohito Yamaguchi, Maria Balasis, Kathy Rocha, Hong-Gang Wang, Victoria Richon, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6382–6389.
https://doi.org/10.1158/1078-0432.CCR-05-0344
Published: 06 September 2005
View articletitled, Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Open the PDF for Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 in another window
Journal Articles

Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3

Free
Purva Bali, Prince George, Pamela Cohen, Jianguo Tao, Fei Guo, Celia Sigua, Anasuya Vishvanath, Anna Scuto, Srinivas Annavarapu, Warren Fiskus, Lynn Moscinski, Peter Atadja, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 4991–4997.
https://doi.org/10.1158/1078-0432.CCR-04-0210
Published: 05 August 2004
View articletitled, Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Open the PDF for Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 in another window